GAVRETO is the only once-daily therapy designed to selectively target RET in mNSCLC1

NCCN Recommended

National Comprehensive Cancer Network® (NCCN®)–recommended as a Category 2A preferred first-line treatment option for RET fusion-positive metastatic NSCLC2*

*See the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC for detailed recommendations, including other preferred treatment options.2
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
mNSCLC=metastatic non–small cell lung cancer; RET=rearranged during transfection.

Financial Assistance
Financial assistance options
for eligible patients
Contact a Representative
Contact a representative
Resources for your patients
Resources for
your patients